Novo Nordisk obtained federal approval for its Novolog FlexTouch and Levemir FlexTouch insulin pens. The new delivery system enables diabetes patients to press a low-dose-force button to administer insulin.
The prices for Sanofi's long-acting insulin Lantus and Novo Nordisk's Levemir have risen in tandem 13 times since 2009, according to a market research firm. Similar patterns were observed with Eli Lilly and Co.'s Humalog and Novo Nordisk's Novolog. Increases have also been seen among competing drugs for multiple sclerosis, erectile dysfunction and allergies.
Children ate about 134 fewer calories per day when they slept 1.5 more hours than usual every night for a week compared with when they got 1.5 fewer hours of sleep, according to a small study in the journal Pediatrics. Children who slept more hours also had lower fasting leptin levels and weighed less at the end of the week.
The FDA has granted Novo Nordisk approval for a pair of its insulin injection pens -- the NovoLog FlexTouch and the Levemir FLexTouch. The devices, slated for U.S. release next year, are each prefilled with 300 units of insulin and work with the company's NovoFine and NovoTwist needles. The pens were approved in Europe two years ago.
The FDA assigned Novo Nordisk's insulin Levemir to pregnancy category B, meaning the diabetes treatment does not increase risk to the fetus. The classification was based on a head-to-head study with another insulin.
Novo Nordisk is looking to update the label of diabetes medicine Levemir to include patients ages 2 to 5. Novo said no children treated with Levemir during a clinical study had a severe hypoglycemic episode compared with 6 children given a human basal insulin who did have an episode.